【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重

智通財經

06-27

【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重控制適應症】智通財經APP訊，信達生物(01801.HK)發佈公告，胰高血糖素(GCG)/胰高血糖素樣肽-1 (GLP-1)雙受體激動劑信爾美®(瑪仕度肽注射液)的新藥上市申請(NDA)獲中國國家藥品監督管理局(NMPA)批准上市，用於成人肥胖或超重患者的長期體重控制。信爾美®是全球首個GCG/GLP-1雙受體激動減重藥物，其獨特的作用機制既能夠增加減重效果，又能夠直接降低內臟脂肪含量，帶來全面的代謝獲益，獲評爲2025年全球十大最受期待藥物之一(FIERCE Pharma 2025)。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546079022"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546079022\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546079022?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-27 16:39","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2546079022","market":"hk","top_or_hot":-1,"title":"【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重控制適應症】</b>智通財經APP訊，信達生物(01801.HK)發佈公告，胰高血糖素(GCG)/胰高血糖素樣肽-1 \n\n(GLP-1)雙受體激動劑信爾美®(瑪仕度肽注射液)的新藥上市申請(NDA)獲中國國家藥品監督管理局(NMPA)批准上市，用於成人肥胖或超重患者的長期體重控制。信爾美®是全球首個GCG/GLP-1雙受體激動減重藥物，其獨特的作用機制既能夠增加減重效果，又能夠直接降低內臟脂肪含量，帶來全面的代謝獲益，獲評爲2025年全球十大最受期待藥物之一(FIERCE \n\nPharma 2025)。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-06-27 16:39</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重控制適應症】</b>智通財經APP訊，信達生物(01801.HK)發佈公告，胰高血糖素(GCG)/胰高血糖素樣肽-1 \n\n(GLP-1)雙受體激動劑信爾美®(瑪仕度肽注射液)的新藥上市申請(NDA)獲中國國家藥品監督管理局(NMPA)批准上市，用於成人肥胖或超重患者的長期體重控制。信爾美®是全球首個GCG/GLP-1雙受體激動減重藥物，其獨特的作用機制既能夠增加減重效果，又能夠直接降低內臟脂肪含量，帶來全面的代謝獲益，獲評爲2025年全球十大最受期待藥物之一(FIERCE \n\nPharma 2025)。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2546079022","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546079022","pubTimestamp":1751013548,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重控制適應症】智通財經APP訊，信達生物(01801.HK)發佈公告，胰高血糖素(","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","GLP":"Global Partners Lp","01801":"信达生物","BK1589":"北水核心资产","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4590":"PTP","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4144":"石油与天然气的储存和运输"},"translate_title":"[Innovent Biologics (01801. HK): The world's first GCG/GLP-1 dual receptor agonistic weight loss drug Xinermei ® (Masidu Peptide Injection) Approved for the First Long-term Weight","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1,"GLP":1},"content_text":"【信達生物(01801.HK)：全球首個GCG/GLP-1雙受體激動減重藥物信爾美® (瑪仕度肽注射液)獲批首個長期體重控制適應症】智通財經APP訊，信達生物(01801.HK)發佈公告，胰高血糖素(GCG)/胰高血糖素樣肽-1 \n\n(GLP-1)雙受體激動劑信爾美®(瑪仕度肽注射液)的新藥上市申請(NDA)獲中國國家藥品監督管理局(NMPA)批准上市，用於成人肥胖或超重患者的長期體重控制。信爾美®是全球首個GCG/GLP-1雙受體激動減重藥物，其獨特的作用機制既能夠增加減重效果，又能夠直接降低內臟脂肪含量，帶來全面的代謝獲益，獲評為2025年全球十大最受期待藥物之一(FIERCE \n\nPharma 2025)。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}